Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial.

ABSTRACT:

Introduction

Rasagiline is a monoamine oxidase B (MAO-B) inhibitor with possible neuroprotective effects in patients with amyotrophic lateral sclerosis (ALS).

Methods

We performed a randomized, double-blind, placebo-controlled trial of 80 ALS participants with enrichment of the placebo group with historical controls (n = 177) at 10 centers in the United States. Participants were randomized in a 3:1 ratio to 2 mg/day rasagiline or placebo. The primary outcome was average slope of decline on the ALS Functional Rating Scale-Revised (ALSFRS-R). Secondary measures included slow vital capacity, survival, mitochondrial and molecular biomarkers, and adverse-event reporting.

Results

There was no difference in the average 12-month ALSFRS-R slope between rasagiline and the mixed

SUBMITTER: Statland JM 

PROVIDER: S-EPMC6545236 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature